Advocacy intelligence hub — real-time data for patient organizations
State University of New York at Buffalo — NA
Sunnybrook Health Sciences Centre
Sanotize Research and Development corp. — PHASE2
University Hospital, Brest — NA
National Cancer Institute (NCI) — PHASE1, PHASE2
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Azacitidine
(AZACITIDINE)Orphan drugstandardDr. Reddy's Laboratories Inc.
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Azacitidine for injection is a pyrimidine nucleoside analog of cytidine. Azacitidine for injection is believed to exert its a...
Azacitidine
(AZACITIDINE FOR)Orphan drugstandardPilnova Pharma Inc
Nucleoside Metabolic Inhibitor [EPC]
12.1 Mechanism of Action Azacitidine is a pyrimidine nucleoside analog of cytidine. Azacitidine is believed to exert its antineoplastic effects by cau...
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
JianWu Dai, Ph.D
Chinese Academy of Sciences
B. Smith, M.S.W., L.C.S.W
Johns Hopkins University
📍 OKLAHOMA CITY, OK
Kyoo H. Lee, MD
Asan Medical Center
Dolores Grosso, DNP, CRNP
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Philip L. McCarthy, MD
Roswell Park Cancer Institute
View all Acquired idiopathic sideroblastic anemia specialists →